Molecular Imaging Biomarkers

Hirmas N, Leyh C, Sraieb M, Barbato F, Schaarschmidt BM, Umutlu L, Nader M, Wedemeyer H, Ferdinandus J, Rischpler C, Herrmann K, Costa PF, Lange CM, Weber M, Fendler WP (2021) (68)Ga-PSMA-11 PET/CT Improves Tumor Detection and Impacts Management in Patients  with Hepatocellular Carcinoma. J Nucl Med 62:1235–1241 . doi.org/10.2967/jnumed.120.257915

Seifert R, Küper A, Tewes M, Heuschmid M, Welt A, Fendler WP, Herrmann K, Decker T (2021) [18F]-Fluorodeoxyglucose Positron Emission Tomography/CT to Assess the Early Metabolic Response in Patients with Hormone Receptor-Positive HER2-Negative Metastasized Breast Cancer Treated with Cyclin-Dependent 4/6 Kinase Inhibitors. Oncol Res Treat 1–8 . doi.org/10.1159/000516422

Kersting D, Jentzen W, Sraieb M, Costa PF, Conti M, Umutlu L, Antoch G, Nader M, Herrmann K, Fendler WP, Rischpler C, Weber M (2021) Comparing lesion detection efficacy and image quality across different PET system generations to optimize the iodine-124 PET protocol for recurrent thyroid cancer. EJNMMI Phys 8:14 . doi.org/10.1186/s40658-021-00361-y

Weber M, Schmitz J, Maric I, Pabst KM, Umutlu L, Walz M, Herrmann K, Rischpler C, Weber F, Jentzen W, Theurer S, Poeppel TD, Unger N, Fendler WP (2021) Diagnostic performance of [(124)I]m-iodobenzylguanidine PET/CT in patients with  pheochromocytoma. J Nucl Med. doi.org/10.2967/jnumed.121.262797

Sciagrà R, Lubberink M, Hyafil F, Saraste A, Slart RHJA, Agostini D, Nappi C, Georgoulias P, Bucerius J, Rischpler C, Verberne HJ (2021) EANM procedural guidelines for PET/CT quantitative myocardial perfusion imaging. Eur J Nucl Med Mol Imaging 48:1040–1069 . doi.org/10.1007/s00259-020-05046-9

Decker T, Seifert R, Bichler M, Birtel A, Fischer G, Nonnenbroich C, Dechow T (2021) Elective Discontinuation of CDK4/6 Inhibitors in Patients with Metastatic Hormone Receptor-Positive, Her-2-Negative Breast Cancer: A Retrospective Single-Center Experience. Oncol Res Treat 1–5 . doi.org/10.1159/000518207

Chodyla M, Demircioglu A, Schaarschmidt BM, Bertram S, Bruckmann NM, Haferkamp J, Li Y, Bauer S, Podleska L, Rischpler C, Forsting M, Herrmann K, Umutlu L, Grueneisen J (2021) Evaluation of (18)F-FDG PET and DWI Datasets for Predicting Therapy Response of  Soft-Tissue Sarcomas Under Neoadjuvant Isolated Limb Perfusion. J Nucl Med 62:348–353 . doi.org/10.2967/jnumed.120.248260

Weber M, Jentzen W, Hofferber R, Herrmann K, Fendler WP, Conti M, Wetter A, Kersting D, Rischpler C, Fragoso Costa P (2021) Evaluation of [(68)Ga]Ga-PSMA PET/CT images acquired with a reduced scan time  duration in prostate cancer patients using the digital biograph vision. EJNMMI Res 11:21 . doi.org/10.1186/s13550-021-00765-y

Weber M, Jentzen W, Hofferber R, Herrmann K, Fendler WP, Rischpler C, Umutlu L, Conti M, Costa PF, Sraieb M, Kersting D (2021) Evaluation of 18F-FDG PET/CT images acquired with a reduced scan time duration in lymphoma patients using the digital biograph vision. BMC Cancer 21:62 . doi.org/10.1186/s12885-020-07723-2

Roll W, Schindler P, Masthoff M, Seifert R, Schlack K, Bögemann M, Stegger L, Weckesser M, Rahbar K (2021) Evaluation of 68Ga-PSMA-11 PET-MRI in Patients with Advanced Prostate Cancer Receiving 177Lu-PSMA-617 Therapy: A Radiomics Analysis. Cancers (Basel) 13: . doi.org/10.3390/cancers13153849

Chodyla M, Demircioglu A, Schaarschmidt BM, Bertram S, Morawitz J, Bauer S, Podleska L, Rischpler C, Forsting M, Herrmann K, Umutlu L, Grueneisen J (2021) Evaluation of the Predictive Potential of 18F-FDG PET and DWI Data Sets for Relevant  Prognostic Parameters of Primary Soft-Tissue Sarcomas. Cancers (Basel) 13: . doi.org/10.3390/cancers13112753

Vardarli I, Weber M, Rischpler C, Führer D, Herrmann K, Weidemann F (2021) Fabry Cardiomyopathy: Current Treatment and Future Options. J Clin Med 10: . doi.org/10.3390/jcm10143026

Fendler WP, Calais J, Eiber M, Simko JP, Kurhanewicz J, Santos RD, Feng FY, Reiter RE, Rettig MB, Nickols NG, Kishan AU, Slavik R, Carroll PR, Lawhn-Heath C, Herrmann K, Czernin J, Hope TA (2021) False positive PSMA PET for tumor remnants in the irradiated prostate and other  interpretation pitfalls in a prospective multi-center trial. Eur J Nucl Med Mol Imaging 48:501–508 . doi.org/10.1007/s00259-020-04945-1

Kessler L, Schlitter AM, Krönke M, von Werder A, Tauber R, Maurer T, Robinson S, Orlandi C, Herz M, Yousefi BH, Nekolla SG, Schwaiger M, Eiber M, Rischpler C (2021) First Experience Using (18)F-Flubrobenguane PET Imaging in Patients with Suspected  Pheochromocytoma or Paraganglioma. J Nucl Med 62:479–485 . doi.org/10.2967/jnumed.120.248021

Roll W, Weckesser M, Seifert R, Bodei L, Rahbar K (2021) Imaging and liquid biopsy in the prediction and evaluation of response to PRRT in neuroendocrine tumors: implications for patient management. Eur J Nucl Med Mol Imaging. doi.org/10.1007/s00259-021-05359-3

Iking J, Staniszewska M, Kessler L, Klose JM, Lückerath K, Fendler WP, Herrmann K, Rischpler C (2021) Imaging Inflammation with Positron Emission Tomography. Biomedicines 9: . doi.org/10.3390/biomedicines9020212

Oubari S, Naser E, Papathanasiou M, Luedike P, Hagenacker T, Thimm A, Rischpler C, Kessler L, Kimmich C, Hegenbart U, Schönland S, Rassaf T, Reinhardt HC, Jöckel K-H, Dürig J, Dührsen U, Carpinteiro A (2021) Impact of time to diagnosis on Mayo stages, treatment outcome, and survival in  patients with AL amyloidosis and cardiac involvement. Eur J Haematol 107:449–457 . doi.org/10.1111/ejh.13681

Ferdinandus J, Fragoso Costa P, Kessler L, Weber M, Hirmas N, Kostbade K, Bauer S, Schuler M, Ahrens M, Schildhaus H-U, Rischpler C, Grafe H, Siveke JT, Herrmann K, Fendler W, Hamacher R (2021) Initial clinical experience with (90)Y-FAPI-46 radioligand therapy for advanced  stage solid tumors: a case series of nine patients. J Nucl Med. doi.org/10.2967/jnumed.121.262468

Weber M, Kersting D, Umutlu L, Schäfers M, Rischpler C, Fendler WP, Buvat I, Herrmann K, Seifert R (2021) Just another “Clever Hans”? Neural networks and FDG PET-CT to predict the outcome of patients with breast cancer. Eur J Nucl Med Mol Imaging. doi.org/10.1007/s00259-021-05270-x

Seitzer KE, Seifert R, Kessel K, Roll W, Schlack K, Boegemann M, Rahbar K (2021) Lutetium-177 Labelled PSMA Targeted Therapy in Advanced Prostate Cancer: Current Status and Future Perspectives. Cancers (Basel). 13

Seifert R, Schäfers MA, Heitplatz B, Kerschke L, Riemann B, Noto B (2021) Minimal extrathyroid extension in papillary micro carcinoma of the thyroid is an independent risk factor for relapse through lymph node and distant metastases. J Nucl Med jnumed.121.261898 . doi.org/10.2967/jnumed.121.261898

Umutlu L, Kirchner J, Bruckmann NM, Morawitz J, Antoch G, Ingenwerth M, Bittner A-K, Hoffmann O, Haubold J, Grueneisen J, Quick HH, Rischpler C, Herrmann K, Gibbs P, Pinker-Domenig K (2021) Multiparametric Integrated 18F-FDG PET/MRI-Based Radiomics for Breast Cancer Phenotyping and Tumor Decoding. Cancers (Basel) 13: . doi.org/10.3390/cancers13122928

Makowski MR, Rischpler C, Ebersberger U, Keithahn A, Kasel M, Hoffmann E, Rassaf T, Kessler H, Wester H-J, Nekolla SG, Schwaiger M, Beer AJ (2021) Multiparametric PET and MRI of myocardial damage after myocardial infarction:  correlation of integrin αvβ3 expression and myocardial blood flow. Eur J Nucl Med Mol Imaging 48:1070–1080 . doi.org/10.1007/s00259-020-05034-z

Hautzel H, Alnajdawi Y, Fendler WP, Rischpler C, Darwiche K, Eberhardt WE, Umutlu L, Theegarten D, Stuschke M, Schuler M, Aigner C, Herrmann K, Plönes T (2021) N-staging in large cell neuroendocrine carcinoma of the lung: diagnostic value of  [(18)F]FDG PET/CT compared to the histopathology reference standard. EJNMMI Res 11:68 . doi.org/10.1186/s13550-021-00811-9

Kessler L, Ferdinandus J, Hirmas N, Zarrad F, Nader M, Kersting D, Weber M, Kazek S, Sraieb M, Hamacher R, Lueckerath K, Umutlu L, Fendler WP, Rischpler C (2021) Pitfalls and common findings in (68)Ga-FAPI-PET – A pictorial analysis. J Nucl Med. doi.org/10.2967/jnumed.121.262808

Slart RHJA, Williams MC, Juarez-Orozco LE, Rischpler C, Dweck MR, Glaudemans AWJM, Gimelli A, Georgoulias P, Gheysens O, Gaemperli O, Habib G, Hustinx R, Cosyns B, Verberne HJ, Hyafil F, Erba PA, Lubberink M, Slomka P, Išgum I, Visvikis D, Kolossváry M, Saraste A (2021) Position paper of the EACVI and EANM on artificial intelligence applications in  multimodality cardiovascular imaging using SPECT/CT, PET/CT, and cardiac CT. Eur J Nucl Med Mol Imaging 48:1399–1413 . doi.org/10.1007/s00259-021-05341-z

Kersting D, Seifert R, Kessler L, Herrmann K, Theurer S, Brandenburg T, Dralle H, Weber F, Umutlu L, Führer-Sakel D, Görges R, Rischpler C, Weber M (2021) Predictive factors for rai-refractory disease and short overall survival in pdtc. Cancers (Basel) 13:1–13 . doi.org/10.3390/cancers13071728

Slart RHJA, Glaudemans AWJM, Gheysens O, Lubberink M, Kero T, Dweck MR, Habib G, Gaemperli O, Saraste A, Gimelli A, Georgoulias P, Verberne HJ, Bucerius J, Rischpler C, Hyafil F, Erba PA (2021) Procedural recommendations of cardiac PET/CT imaging: standardization in  inflammatory-, infective-, infiltrative-, and innervation (4Is)-related cardiovascular diseases: a joint collaboration of the EACVI and the EANM. Eur J Nucl Med Mol Imaging 48:1016–1039 . doi.org/10.1007/s00259-020-05066-5

Bruckmann NM, Kirchner J, Umutlu L, Fendler WP, Seifert R, Herrmann K, Bittner A-K, Hoffmann O, Mohrmann S, Antke C, Schimmöller L, Ingenwerth M, Breuckmann K, Stang A, Buchbender C, Antoch G, Sawicki LM (2021) Prospective comparison of the diagnostic accuracy of 18F-FDG PET/MRI, MRI, CT, and bone scintigraphy for the detection of bone metastases in the initial staging of primary breast cancer patients. Eur Radiol. doi.org/10.1007/s00330-021-07956-0

Morawitz J, Kirchner J, Martin O, Bruckmann N-M, Dietzel F, Li Y, Rischpler C, Herrmann K, Umutlu L, Bittner A-K, Mohrmann S, Ingenwerth M, Häberle L, Esposito I, Antoch G, Buchbender C, Sawicki LM (2021) Prospective Correlation of Prognostic Immunohistochemical Markers With SUV and ADC  Derived From Dedicated Hybrid Breast 18F-FDG PET/MRI in Women With Newly Diagnosed Breast Cancer. Clin Nucl Med 46:201–205 . doi.org/10.1097/RLU.0000000000003488

Alberts IL, Seifert R, Rahbar K, Afshar-Oromieh A (2021) Prostate Cancer Theranostics. PET Clin 16:383–390 . doi.org/10.1016/j.cpet.2021.03.003

Seifert R, Alberts IL, Afshar-Oromieh A, Rahbar K (2021) Prostate Cancer Theranostics. PET Clin 16:391–396 . doi.org/10.1016/j.cpet.2021.03.004

Barbato F, Fendler WP, Rauscher I, Herrmann K, Wetter A, Ferdinandus J, Seifert R, Nader M, Rahbar K, Hadaschik B, Eiber M, Gafita A, Weber M (2021) PSMA-PET for the assessment of metastatic hormone-sensitive prostate cancer volume of disease. J Nucl Med jnumed.121.262120 . doi.org/10.2967/jnumed.121.262120

Fragoso Costa P, Jentzen W, SÜßELBECK F, Fendler WP, Rischpler C, Herrmann K, Conti M, Kersting D, Weber M (2021) Reduction of emission time for [68Ga]Ga-PSMA PET/CT using the digital biograph  vision: a Phantom study. Q J Nucl Med Mol imaging  Off  Publ Ital Assoc Nucl Med [and] Int Assoc Radiopharmacol (IAR), [and] Sect Soc of. doi.org/10.23736/S1824-4785.21.03300-8

Seifert R, Sandach P, Kersting D, Fendler WP, Hadaschik B, Herrmann K, Sunderland J, Pollard J (2021) Repeatability of 68 Ga-PSMA-HBED-CC PET/CT-derived total molecular tumor volume. J Nucl Med jnumed.121.262528 . doi.org/10.2967/jnumed.121.262528

Kersting D, Jentzen W, Fragoso Costa P, Sraieb M, Sandach P, Umutlu L, Conti M, Zarrad F, Rischpler C, Fendler WP, Herrmann K, Weber M (2021) Silicon-photomultiplier-based PET/CT reduces the minimum detectable activity of  iodine-124. Sci Rep 11:17477 . doi.org/10.1038/s41598-021-95719-8

Michel L, Helfrich I, Hendgen-Cotta UB, Mincu R-I, Korste S, Mrotzek SM, Spomer A, Odersky A, Rischpler C, Herrmann K, Umutlu L, Coman C, Ahrends R, Sickmann A, Löffek S, Livingstone E, Ugurel S, Zimmer L, Gunzer M, Schadendorf D, Totzeck M, Rassaf T (2021) Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor  therapy. Eur Heart J. doi.org/10.1093/eurheartj/ehab430

Pabst KM, Decker T, Kersting D, Bartel T, Sraieb M, Herrmann K, Seifert R (2021) The Future Role of PET Imaging in Metastatic Breast Cancer. Oncol Res Treat. doi.org/10.1159/000521079

Ahmadzadehfar H, Matern R, Baum RP, Seifert R, Kessel K, Bögemann M, Kratochwil C, Rathke H, Ilhan H, Svirydenka H, Sathekge M, Kabasakal L, Yordanova A, Garcia-Perez FO, Kairemo K, Maharaj M, Paez D, Virgolini I, Rahbar K (2021) The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [177Lu]Lu-PSMA-617: a WARMTH multicentre study. Eur J Nucl Med Mol Imaging. doi.org/10.1007/s00259-021-05383-3

Seifert R, Kessel K, Schlack K, Weckesser M, Kersting D, Seitzer KE, Weber M, Bögemann M, Rahbar K (2021) Total tumor volume reduction and low PSMA expression in patients receiving Lu-PSMA therapy. Theranostics 11:8143–8151 . doi.org/10.7150/thno.60222

Murray JM, Pfeffer P, Seifert R, Hermann A, Handke J, Kummer L, Janssen H, Weigand MA, Schlemmer H-P, Larmann J, Kleesiek J (2021) Vesseg: An Open-Source Tool for Deep Learning-Based Atherosclerotic Plaque Quantification in Histopathology Image. Arterioscler Thromb Vasc Biol. doi.org/10.1161/ATVBAHA.121.316124

Kessler L, Kupusovic J, Ferdinandus J, Hirmas N, Umutlu L, Zarrad F, Nader M, Fendler WP, Totzeck M, Wakili R, Schlosser T, Rassaf T, Rischpler C, Siebermair J (2021) Visualization of Fibroblast Activation After Myocardial Infarction Using 68Ga-FAPI  PET. Clin Nucl Med 46:807–813 . doi.org/10.1097/RLU.0000000000003745

Kupusovic J, Kessler L, Nekolla SG, Riesinger L, Weber MM, Ferdinandus J, Kochhäuser S, Rassaf T, Wakili R, Rischpler C, Siebermair J (2021) Visualization of thermal damage using (68) Ga-FAPI-PET/CT after pulmonary vein  isolation. Eur J Nucl Med Mol Imaging. doi.org/10.1007/s00259-021-05612-9

Papathanasiou M, Carpinteiro A, Hagenacker T, Herrmann K, Rassaf T, Rischpler C, Luedike P (2020) (18)F-florbetaben positron emission tomography detects cardiac involvement in  systemic AA amyloidosis. Eur J Nucl Med Mol Imaging 47:3186–3187 . doi.org/10.1007/s00259-020-04861-4

Strack C, Seifert R, Kleesiek J (2020) Artificial intelligence in hybrid imaging. Radiologe. doi.org/10.1007/s00117-020-00646-w

Büther F, Jones J, Seifert R, Stegger L, Schleyer P, Schäfers M (2020) Clinical evaluation of a data-driven respiratory gating algorithm for whole-body positron emission tomography with continuous bed motion. J Nucl Med jnumed.119.235770 . doi.org/10.2967/jnumed.119.235770

Rahbar K, Afshar-Oromieh A, Seifert R, Wagner S, Schäfers M, Bögemann M, Weckesser M (2020) Do fasting or high caloric drinks affect the physiological uptake of fluorine-18 prostate-specific membrane antigen-1007 in liver and bowel? World J Nucl Med 19:220 . doi.org/10.4103/wjnm.WJNM_6_19

Vitadello T, Kunze KP, Nekolla SG, Langwieser N, Bradaric C, Weis F, Cassese S, Fusaro M, Hapfelmeier A, Lewalter T, Schwaiger M, Kastrati A, Laugwitz K-L, Rischpler C, Ibrahim T (2020) Hybrid PET/MR imaging for the prediction of left ventricular recovery after  percutaneous revascularisation of coronary chronic total occlusions. Eur J Nucl Med Mol Imaging 47:3074–3083 . doi.org/10.1007/s00259-020-04877-w

Dittmann M, Gonzalez Carvalho JM, Rahbar K, Schäfers M, Claesener M, Riemann B, Seifert R (2020) Incremental diagnostic value of [18F]tetrafluoroborate PET-CT compared to [131I]iodine scintigraphy in recurrent differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. doi.org/10.1007/s00259-020-04727-9

Backhaus P, Roll W, Beuker C, Zinnhardt B, Seifert R, Wenning C, Eisenblätter M, Thomas C, Schmidt-Pogoda A, Strunk D, Wagner S, Faust A, Tüttelmann F, Röpke A, Jacobs AH, Stummer W, Wiendl H, Meuth SG, Schäfers M, Grauer O, Minnerup J (2020) Initial experience with [18F]DPA-714 TSPO-PET to image inflammation in primary angiitis of the central nervous system. Eur J Nucl Med Mol Imaging. doi.org/10.1007/s00259-019-04662-4

Scherer J, Nolden M, Kleesiek J, Metzger J, Kades K, Schneider V, Bach M, Sedlaczek O, Bucher AM, Vogl TJ, Grünwald F, Kühn J-P, Hoffmann R-T, Kotzerke J, Bethge O, Schimmöller L, Antoch G, Müller H-W, Daul A, Nikolaou K, la Fougère C, Kunz WG, Ingrisch M, Schachtner B, Ricke J, Bartenstein P, Nensa F, Radbruch A, Umutlu L, Forsting M, Seifert R, Herrmann K, Mayer P, Kauczor H-U, Penzkofer T, Hamm B, Brenner W, Kloeckner R, Düber C, Schreckenberger M, Braren R, Kaissis G, Makowski M, Eiber M, Gafita A, Trager R, Weber WA, Neubauer J, Reisert M, Bock M, Bamberg F, Hennig J, Meyer PT, Ruf J, Haberkorn U, Schoenberg SO, Kuder T, Neher P, Floca R, Schlemmer H-P, Maier-Hein K (2020) Joint Imaging Platform for Federated Clinical Data Analytics. JCO Clin Cancer Informatics 1027–1038 . doi.org/10.1200/CCI.20.00045

Kessel K, Seifert R, Weckesser M, Roll W, Humberg V, Schlack K, Bögemann M, Bernemann C, Rahbar K (2020) Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving 177Lu-PSMA-617 Radioligand Therapy. Theranostics 10:7645–7655 . doi.org/10.7150/thno.44556

Ahmadzadehfar H, Rahbar K, Baum RP, Seifert R, Kessel K, Bögemann M, Kulkarni HR, Zhang J, Gerke C, Fimmers R, Kratochwil C, Rathke H, Ilhan H, Maffey-Steffan J, Sathekge M, Kabasakal L, Garcia-Perez FO, Kairemo K, Maharaj M, Paez D, Virgolini I (2020) Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial). Eur J Nucl Med Mol Imaging. doi.org/10.1007/s00259-020-04797-9

Slart RHJA, Glaudemans AWJM, Gheysens O, Lubberink M, Kero T, Dweck MR, Habib G, Gaemperli O, Saraste A, Gimelli A, Georgoulias P, Verberne HJ, Bucerius J, Rischpler C, Hyafil F, Erba PA (2020) Procedural recommendations of cardiac PET/CT imaging: standardization in  inflammatory-, infective-, infiltrative-, and innervation- (4Is) related cardiovascular diseases: a joint collaboration of the EACVI and the EANM: summary. Eur Hear journal Cardiovasc Imaging 21:1320–1330 . doi.org/10.1093/ehjci/jeaa299

Seifert R, Kessel K, Schlack K, Weber M, Herrmann K, Spanke M, Fendler WP, Hadaschik B, Kleesiek J, Schäfers M, Weckesser M, Boegemann M, Rahbar K (2020) PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis. Eur J Nucl Med Mol Imaging. doi.org/10.1007/s00259-020-05040-1

Seifert R, Kessel K, Schlack K, Weckesser M, Bögemann M, Rahbar K (2020) Radioligand therapy using [177Lu]Lu-PSMA-617 in mCRPC: a pre-VISION single-center analysis. Eur J Nucl Med Mol Imaging. doi.org/10.1007/s00259-020-04703-3

Papathanasiou M, Carpinteiro A, Kersting D, Jakstaite A-M, Hagenacker T, Schlosser T-W, Rischpler C, Rassaf T, Luedike P (2020) Rare variant (p.Ser43Asn) of familial transthyretin amyloidosis associated with  isolated cardiac phenotype: A case series with literature review. Mol Genet genomic Med e1581 . doi.org/10.1002/mgg3.1581

Müther M, Roll W, Brokinkel B, Zinnhardt B, Sporns PB, Seifert R, Schäfers M, Weckesser M, Stegger L, Stummer W, Rahbar K (2020) Response assessment of somatostatin receptor targeted radioligand therapies for progressive intracranial meningioma. Nuklearmedizin. doi.org/10.1055/a-1200-0989

Seifert R, Herrmann K, Kleesiek J, Schafers MA, Shah V, Xu Z, Chabin G, Garbic S, Spottiswoode B, Rahbar K (2020) Semi-automatically quantified tumor volume using Ga-68-PSMA-11-PET as biomarker for survival in patients with advanced prostate cancer. J Nucl Med 10.2967/jnumed.120.242057 . doi.org/10.2967/jnumed.120.242057

Roll W, Müther M, Sporns PB, Zinnhardt B, Molina ES, Seifert R, Schäfers M, Weckesser M, Stegger L, Beule AG, Stummer W, Rahbar K (2020) Somatostatin receptor targeted radioligand therapy in head and neck paraganglioma. World Neurosurg. doi.org/10.1016/j.wneu.2020.07.165

Kersting D, Guberina N, Umutlu L, Stuschke M, Hautzel H (2020) Superior Vena Cava Syndrome Induced Collateral Circulation on 99mTc-Macroaggregated  Albumin Lung Perfusion Scintigraphy. Clin Nucl Med 45:e435–e438 . doi.org/10.1097/RLU.0000000000003127

Sibille L, Seifert R, Avramovic N, Vehren T, Spottiswoode B, Zuehlsdorff S, Schäfers M (2019) 18 F-FDG PET/CT Uptake Classification in Lymphoma and Lung Cancer by Using Deep Convolutional Neural Networks. Radiology 191114 . doi.org/10.1148/radiol.2019191114

Seifert R, Schafigh D, Hoffmeier A, Huss S, Weckesser M, Rahbar K (2019) FDG‐PET proves to be reliable in the diagnostic workup of a rare cardiac hemangioma. J Card Surg jocs.14197 . doi.org/10.1111/jocs.14197

Kersting D, Fasbender S, Pilch R, Kurth J, Franken A, Ludescher M, Naskou J, Hallenberger A, Gall C von, Mohr CJ, Lukowski R, Raba K, Jaschinski S, Esposito I, Fischer JC, Fehm T, Niederacher D, Neubauer H, Heinzel T (2019) From in vitro to ex vivo: subcellular localization and uptake of graphene quantum  dots into solid tumors. Nanotechnology 30:395101 . doi.org/10.1088/1361-6528/ab2cb4

Kessel K, Seifert R, Schäfers M, Weckesser M, Schlack K, Boegemann M, Rahbar K (2019) Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving 177 Lu-PSMA-617. Theranostics 9:4841–4848 . doi.org/10.7150/thno.35759

Rahbar K, Ahmadzadehfar H, Seifert R, Boegemann M (2018) [ 177 Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer. Lancet Oncol 19:e371 . doi.org/10.1016/S1470-2045(18)30410-8

Rahbar K, Afshar-Oromieh A, Seifert R, Wagner S, Schäfers M, Bögemann M, Weckesser M (2018) Diagnostic performance of 18F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer. Eur J Nucl Med Mol Imaging 45:2055–2061 . doi.org/10.1007/s00259-018-4089-x

Seifert R, Kuhlmann MT, Eligehausen S, Kiefer F, Hermann S, Schafers M (2018) Molecular imaging of MMP activity discriminates unstable from stable plaque phenotypes in shear-stress induced murine atherosclerosis. PLoS One 13:e0204305 . doi.org/10.1371/journal.pone.0204305

Seifert R, Scherzinger A, Kiefer F, Hermann S, Jiang X, Schäfers MA (2017) Statistical Permutation-based Artery Mapping (SPAM): a novel approach to evaluate imaging signals in the vessel wall. BMC Med Imaging 17:1–11 . doi.org/10.1186/s12880-017-0207-7